Vishnu Murthy, of the David Geffen School of Medicine at UCLA, discusses the results and implications of the study he co-authored that examined the efficacy and toxicity of 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer in a real-world setting. Murthy presented the abstract at the 2024 SNMMI Annual Meeting.
Efficacy and Toxicity of 177Lu-PSMA-617 for mCRPC in a Real-World Setting
By Vishnu Murthy - Last Updated: July 8, 2024Related Posts
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.
Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.
New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.